Hygieia Biotech Wraps Up Successful Showcase of Ca□AKG and Biosynthetic Nutraceutical Ingredients at CPHI Korea 2026

SHENZHEN, CHINA, September 7, 2026 /EINPresswire.com/ -- SEOUL, South Korea — Hygieia Biotech successfully concluded its participation in CPHI Korea 2026, held at the COEX Convention & Exhibition Center in Seoul. At Booth F28, the company presented a focused portfolio of nutraceutical and functional ingredients for healthy aging, cellular health, women's health, energy support, antioxidant protection and brain health.





The exhibition provided an opportunity for Hygieia to connect directly with supplement brands, ingredient distributors, formulators, manufacturers and industry professionals from Korea and other international markets.
Rather than focusing on a single ingredient, Hygieia used CPHI Korea 2026 to demonstrate how its biosynthetic ingredient portfolio can support different product□development strategies, from healthy aging and cellular health to women's wellness and brain health.

CPHI Korea 2026: Connecting with Global Nutraceutical Partners
At Booth F28, discussions with visitors covered ingredient specifications, quality requirements,

application concepts, manufacturing capabilities and documentation for commercial supplement projects.

The conversations reflected the increasingly comprehensive requirements of B2B customers when evaluating nutraceutical ingredient suppliers. Beyond ingredient availability, brands and manufacturers are also looking for consistent quality, technical support, reliable documentation and scalable supply capabilities.





[Ca-AKG] Takes Center Stage at Booth F28

Calcium Alpha-Ketoglutarate (Ca-AKG), including Hygieia's EnerLive® Ca-AKG, was a major focus of discussions at the exhibition.

Ca-AKG is a functional ingredient associated with cellular metabolism and healthy aging research, making it relevant to supplement concepts focused on healthy aging, metabolic support and cellular vitality.

At CPHI Korea, discussions around Ca-AKG included:

- Ingredient specifications and quality requirements
- Bulk raw-material sourcing
- Application and formulation considerations
- Technical and quality documentation
- Product-development opportunities
- Long-term supply planning

Hygieia's EnerLive® Ca-AKG is supported by technical and scientific documentation for B2B ingredient evaluation, helping supplement brands, manufacturers and distributors assess the ingredient during supplier qualification and product-development stages.

By combining ingredient supply with technical support, Hygieia aims to help customers move from initial ingredient evaluation toward commercial product development and long-term supply.

A Diversified Portfolio of Functional Ingredients

While Ca□AKG was a major focus at CPHI Korea 2026, Hygieia also presented a broader portfolio covering several key areas of the nutraceutical market.

The portfolio included:

□Cellular Health and Antioxidant Support: S□Allyl□L□Cysteine (SAC), Urolithin A and Spermidine
□Women's Health: D□Chiro□Inositol, L□5-MTHF□Ca and S□Equol
□NAD+ and Energy: NMN and Ca□AKG

Together, these ingredients reflect Hygieia's strategy of developing a diversified functional ingredient portfolio that can support different product concepts and formulation requirements.

Rather than limiting its offering to individual ingredients, Hygieia works with customers to explore ingredient selection, formulation requirements and potential product□development opportunities based on specific market needs.

Biosynthetic Manufacturing and Quality Control

Behind Hygieia's ingredient portfolio is its focus on biosynthetic manufacturing, enzyme engineering and controlled production processes.

The company's Zymevolver® platform integrates strain engineering, enzyme optimization and biosynthetic process development to support the efficient and consistent production of selected functional ingredients.

Compared with conventional chemical synthesis or extraction approaches, biosynthetic production can offer advantages in areas such as process control, molecular specificity and manufacturing consistency, depending on the individual ingredient and production pathway.

For B2B customers, however, manufacturing technology is only one part of supplier evaluation. Consistent specifications, quality control and reliable documentation are equally important.

Hygieia therefore supports ingredient evaluation and product□development projects with documentation such as:

□Product specifications
□Certificates of Analysis (COA)
□Safety Data Sheets (SDS)
□Quality and testing documentation
□Stability□related information where applicable
□Regulatory and compliance documentation according to project requirements

This approach helps customers evaluate ingredients more efficiently during supplier qualification and commercial product development.

Supporting B2B Ingredient and Product Development

A key theme throughout CPHI Korea 2026 was the growing need for ingredient suppliers that can provide support beyond bulk raw□material supply.

For supplement brands, manufacturers and distributors, ingredient sourcing is often only the beginning of the product□development process. Technical documentation, formulation considerations, dosage□form requirements and production planning can also play important

roles.
Hygieia supports customers through several stages of this process, including:
□Bulk Ingredient Supply: Functional and nutraceutical raw materials for commercial product development.
□Technical and Quality Support: Specifications, COA, SDS and other relevant documentation for supplier evaluation and product development.
□Formulation Support: Technical assistance for customers developing supplement products based on specific ingredients, dosage forms and applications.
□OEM and ODM Manufacturing: Support for brands seeking finished□product manufacturing, custom formulations and private□label solutions.

This integrated model allows Hygieia to work with customers at different stages, from initial ingredient sourcing and evaluation to formulation development and commercial production planning.

Looking Ahead to Vitafoods Asia 2026
Following its participation in CPHI Korea 2026, Hygieia Biotech is preparing for its next major industry exhibition in Asia.
The company will participate in Vitafoods Asia 2026, taking place September 2□4, 2026, at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand.
Hygieia will exhibit at Booth H7□S41, where the company will showcase selected nutraceutical and functional ingredients, with Ca□AKG, NMN and D□Chiro□Inositol among the key highlights.
The exhibition will provide another opportunity for supplement brands, ingredient distributors, manufacturers and formulators to discuss:
□Functional ingredient sourcing
□Healthy aging and cellular health products
□Women's health formulations
□NAD+ and energy□related ingredients
□Bulk supply requirements
□Formulation development
□OEM and private□label opportunities
Hygieia welcomes industry professionals attending Vitafoods Asia 2026 to visit Booth H7□S41 and discuss ingredient specifications, samples, documentation, formulation requirements and commercial supply opportunities with its technical and sales teams.

Building Long□Term B2B Ingredient Partnerships
CPHI Korea 2026 provided Hygieia Biotech with an opportunity to engage directly with international nutraceutical companies and gain a deeper understanding of the ingredient requirements of brands, manufacturers and distributors.
Going forward, Hygieia will continue to focus on biosynthetic ingredient innovation, reliable manufacturing and responsive B2B technical support.
With a growing portfolio covering healthy aging, cellular health, women's health, energy, antioxidant support and brain health, Hygieia aims to provide flexible ingredient sourcing and

product development solutions for customers in global markets.
For businesses evaluating new nutraceutical ingredients or planning upcoming supplement projects, Hygieia's team is available to discuss ingredient specifications, samples, documentation, formulation requirements and commercial supply opportunities.

Shenzhen Hygieia Biotech Co.Ltd.
Shenzhen Hygieia Biotech Co.Ltd.
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/940270458

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.